Publications by authors named "M A Fernandez-Galan"
Isolated attosecond pulse (IAP) generation usually involves the use of short-medium gas cells operated at high pressures. In contrast, long-medium schemes at low pressures are commonly perceived as inherently unsuitable for IAP generation due to the nonlinear phenomena that challenge favourable phase-matching conditions. Here we provide clear experimental evidence on the generation of isolated extreme-ultraviolet attosecond pulses in a semi-infinite gas cell, demonstrating the use of extended-medium geometries for effective production of IAPs.
View Article and Find Full Text PDFArticle Synopsis
- The COVID-19 pandemic has severely affected individuals with hematological malignancies due to their weakened immune systems, resulting in higher mortality rates and severe outcomes.
- Data from the EPICOVIDEHA registry, which compiles COVID-19 cases from these patients worldwide, was collected from 2020 to 2022, including 8,767 cases from 152 centers across 41 countries.
- Findings show a significant drop in critical infections and overall mortality rates, but hospitalization (especially in ICU) remains a serious risk factor; vaccination is linked to better survival outcomes, highlighting the need for ongoing monitoring and support for these patients.
Background: The availability of multiple treatments for type 1 Gaucher disease increases the need for real-life studies to evaluate treatment efficacy and safety and provide clinicians with more information to choose the best personalized therapy for their patients.
Aims: To determine whether treatment with eliglustat produces, in adult GD1 patients, ans optimal response in daily clinical practice.
Methods: We designed a real-life study with 2 years of follow-up (TRAZELGA [GEE-ELI-2017-01]) to uniformly evaluate the response and adverse events to eliglustat treatment.
Article Synopsis
- Enzymatic replacement therapy (ERT) has significantly improved early diagnosis and management of Gaucher disease (GD) in pediatric patients since its introduction in Spain in 1993, with 386 patients registered in the Spanish Registry of Gaucher Disease.
- The study reviewed data from 98 pediatric patients, revealing that those diagnosed after 1995 had earlier diagnoses and were generally less severe than those diagnosed before 1994, who demonstrated worse complications at presentation.
- Patients in the later cohort (≥1995) started ERT much sooner after diagnosis compared to earlier diagnosed patients (1.6 years vs. 5.2 years), indicating an overall improvement in treatment timing and outcomes for pediatric GD cases.
We report data from a prospective, observational study (ZAGAL) evaluating miglustat 100mg three times daily orally. in treatment-naïve patients and patients with type 1 Gaucher Disease (GD1) switched from previous enzyme replacement therapy (ERT). Clinical evolution, changes in organ size, blood counts, disease biomarkers, bone marrow infiltration (S-MRI), bone mineral density by broadband ultrasound densitometry (BMD), safety and tolerability annual reports were analysed.
View Article and Find Full Text PDF